Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Belzutifan / MK-6482 for the Treatment of Advanced Pheochromocytoma / Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)

Multiple Cancer Types

This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma / paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
Endocrine, Pancreatic
II
Das, Satya
NCT04924075
VICCMD2132

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: